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multicenter experience
Vinnie Bapat,1 Leo Ihlberg,2 Zhan Yun Lim,1 David Hildick-Smith,3 Sabine Bleiziffer,4
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OBJECTIVES To evaluate feasibility and outcome of Transaortic (TAo) transcatheter
Lotus valve implantation.
BACKGROUND The LOTUS (Boston Scientiﬁc, MA, USA) device is a mechanically
expanded, re-sheathable, and repositionable transcatheter aortic valve replacement
(TAVR) prosthesis that has shown favorable safety and efﬁcacy outcomes through 1
year in the REPRISE II trial. A signiﬁcant number of TAVR patients, however, are not
suitable for transfemoral (TF) approach. In such patients, a TAo approach with a
partial sternotomy could be utilized successfully with the LOTUS device. This abstract
will present a multi-centre experience on this approach.METHODS Between July 2014 to December 2014 19 patients with aortic annulus
20–27mm who were considered high-surgical-risk by a multidisciplinary heart team
underwent TAo implantation of Lotus valve in 5 hospitals in Europe. None of the
patients were deemed suitable for the TF approach.
RESULTS The mean age was 77.5 +/- 10.9 years with predominantly female patients
(n¼17). Mean Logistic Euroscore was 20.0 +/- 11.3% and STS score of 5.30 +/- 3.12%.
Mean AVA was 0.58 +/- 0.24cm2 with a mean gradient across aortic valve was 50.4 +/-
12.7mmHg. Valve sizes utilized were 23mm in 10, 25mm in 4 and 27mm in 5 patients.
Implant success was 100%. The post TAVR mean aortic valve gradient was 7.0 +/-
3.9mmHg. There were no cases with more than mild paravalvular leak. There were no
procedural mortality. 30 day all cause mortality was 0%. There was 1 major stroke
(5,26%) and 1 minor stroke (5.26%). There were 2 minor bleeding complications
(10.5%). There was one acute kidney injury (5.26%), one permanent pacemaker im-
plantation (5.26%), no vascular complications or coronary obstruction requiring
intervention.
CONCLUSION TAo implantation of Lotus valve is feasible with excellent outcome in
patients unsuitable for TF approach using the same delivery system.
